Development of a three-microneedle device for hypodermic drug delivery and clinical application.

Department of Plastic and Reconstructive Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Plastic and Reconstructive Surgery (Impact Factor: 3.33). 08/2012; 130(2):451-5. DOI: 10.1097/PRS.0b013e3182589f56
Source: PubMed

ABSTRACT There is a potential use for intradermic or hypodermic drug delivery in skin surgery or aesthetic surgery. Hypodermic delivery with the use of a noninvasive device can be a more useful, reliable, and effective administration route to obtain higher compliance. The authors developed a microneedle device composed of three fine needles (three-microneedle device). The tip of each needle was fabricated with a bevel angle to release a drug broadly into the tissue in a horizontal fashion. In this study, the authors investigated the usefulness of this newly developed three-microneedle device for hypodermic liquid injection, focusing on the optimum insertion depth and the diffusion of injected materials to the tissue. The authors also assessed the efficacy of and patient satisfaction with three-microneedle device injections of botulinum toxin type A for wrinkle reduction in patients with glabellar rhytides. The three-microneedle device yielded consistent results in hypodermal diffusion. On India ink diffusion test and ultrasonographic imaging, three-microneedle device injection showed a broad diffusion in horizontal extension, as compared with usual 31-gauge needle injection. The efficiency and satisfaction of the patients receiving botulinum toxin type A with the three-microneedle device were highly rated. Three-microneedle device delivery enables accurate and broad diffusion of injected substances, thus reducing the total dose and/or injection number of drugs. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Botulinum toxin type A (BTX-A) is widely used for facial esthetics but is incompletely studied. This study was conducted to evaluate the efficacy and safety of BTX-A treatment of glabellar lines. Patients with moderate to severe glabellar lines at maximum frown received intramuscular injections of 20 U BTX-A (BOTOX, Allergan, Inc, Irvine, Calif) or placebo into 5 glabellar sites. Patients were followed up for 120 days after injection. Outcome measures were physician rating of glabellar line severity at maximum frown and rest, patient assessment of improvement, and vital sign and adverse event monitoring. Two hundred sixty-four patients were enrolled (BTX-A: 203, placebo: 61). There was a significantly greater reduction in glabellar line severity with BTX-A than with placebo (all measures, every follow-up visit; P <.022). The effect was maintained for many patients through day 120. There was a low occurrence (5.4%) of mostly mild blepharoptosis in the BTX-A group. BTX-A injections are safe and effective in reducing the severity of glabellar lines.
    Journal of the American Academy of Dermatology 06/2002; 46(6):840-9. · 5.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Botulinum toxin type A treatment is a safe and effective treatment for facial lines. Patient satisfaction with treatment has not yet been systematically measured and reported. To create a valid and reliable questionnaire to assess patient satisfaction with facial line treatment and to assess treatment satisfaction in facial line patients. Development of the Facial Line Treatment Satisfaction (FTS) Questionnaire followed the five-step process recommended by the Patient Reported Outcomes Harmonization Committee. One hundred fifty-two pilot test participants received botulinum toxin type A treatment alone or in combination with a minimally invasive facial line treatment and were satisfied or very satisfied with their facial lines treatment. The FTS is a valid and reliable 14-item questionnaire that measures an aesthetic patient's satisfaction with facial line treatment. The FTS can be used in clinical practice or clinical trials of facial line treatments. Botulinum toxin type A treatment is associated with high patient satisfaction.
    Dermatologic Surgery 06/2003; 29(5):444-9; discussion 449. · 1.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The determination of human skin thickness has been achieved through various methods, both in vivo and in vitro. Ultrasound and histometric analyses have been the most commonly used. However, absolute values of epidermal and dermal thicknesses have demonstrated variability among the different modalities, leaving questions regarding the ability to standardize or compare results of different studies. A cadaver study was designed to examine skin thicknesses in multiple anatomical sites from the same subject. Using three fresh adult cadavers, skin biopsy specimens were obtained at 15 facial sites that were identified as clinically relevant locations: upper lip vermilion, lower lip vermilion, philtral column, chin, upper eyelid, lower eyelid, brow/forehead, submental crease, right cheek, left cheek, right neck, left neck, malar eminence, nasal dorsum, and nasal tip. Histometric measurements were obtained at each location. In all subjects, the upper eyelid had the thinnest skin and was used as the denominator to calculate relative ratios of skin thicknesses with respect to other sites of the face. Using the upper eyelid average skin thickness, the nasal tip skin thickness was 3.30 times thicker and the brow/forehead was 2.8 times thicker. The authors propose a standardized and clinically useful method of skin thickness analysis by defining the relative thickness index. By examining relative values of skin thickness, using each subject as his or her own control, the authors demonstrated consistent ratios of dermal and epidermal thickness from one facial site to another.
    Plastic and Reconstructive Surgery 06/2005; 115(6):1769-73. · 3.33 Impact Factor